OTHER GROUP COMPANIES
market

Kimia Biosciences gets permission for Bemopedoic acid bulk drug; Stock gains near 3%

The permission has been granted by Directorate General of Health Services Central Drugs Standard Control Organization.

May 18, 2022 9:18 IST | India Infoline News Service
Kimia Biosciences Ltd has been granted permission to manufacture and marketing of Bemopedoic acid Bulk Drug under New Drug and Clincial Trials Rules, 2019, under Drug & Cosmetics Acts, 1940 for manufacture and market of Bempedoic acid Bulk Drug.

As per the filing, the permission has been granted by Directorate General of Health Services Central Drugs Standard Control Organisation (New Drug Division) vide letter dated May 17, 2022.

At around 9:20 AM, Kimia Biosciences was trading at Rs39.85 per piece higher by 2.71% on the BSE.

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity